Bayer's finerenone meets primary goal in Phase III

11 May 2021
bayer_large

German pharma and crop sciences company Bayer’s (BAYN: DE) Phase III study FIGARO-DKD, evaluating the efficacy and safety of the investigational drug finerenone versus placebo when added to standard of care in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), has met its primary endpoint, showing that finerenone significantly reduced the composite risk of time to first occurrence of cardiovascular (CV) death or non-fatal CV events (myocardial infarction, stroke, or heart failure hospitalization).

Compared to FIDELIO-DKD, the first of the two Phase III studies investigating finerenone in patients with CKD and T2D, FIGARO-DKD included more patients with earlier stage CKD and T2D, Bayer noted.

Berenberg and Deutsche Bank analysts have previously suggested potential sales for finerenone of $1.8 billion and $2.0 billion, respectively.

“An estimated 160 million patients globally are living with chronic kidney disease and type 2 diabetes, and they are at high risk of experiencing cardiovascular events, as well as progressing to kidney failure,” said Prof Luis Ruilope, Professor at the Cardiorenal Translational Laboratory and Hypertension Unit, Institute of Research imas12, Madrid, Spain, and co-principal investigator of the FIGARO-DKD trial.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical